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Abstract
Myotonic Dystrophy Type-2 (DM2) is an autosomal dominant disease caused by the expansion of a CCTG tetraplet repeat. It
is a multisystemic disorder, affecting skeletal muscles, the heart, the eye, the central nervous system and the endocrine
system. Since microRNA (miRNA) expression is disrupted in Myotonic Dystrophy Type-1 and many other myopathies,
miRNAs deregulation was studied in skeletal muscle biopsies of 13 DM2 patients and 13 controls. Eleven miRNAs were
deregulated: 9 displayed higher levels compared to controls (miR-34a-5p, miR-34b-3p, miR-34c-5p, miR-146b-5p, miR-208a,
miR-221-3p and miR-381), while 4 were decreased (miR-125b-5p, miR-193a-3p, miR-193b-3p and miR-378a-3p). To explore
the relevance of DM2 miRNA deregulation, the predicted interactions between miRNA and mRNA were investigated. Global
gene expression was analyzed in DM2 and controls and bioinformatic analysis identified more than 1,000 miRNA/mRNA
interactions. Pathway and function analysis highlighted the involvement of the miRNA-deregulated mRNAs in multiple
aspects of DM2 pathophysiology. In conclusion, the observed miRNA dysregulations may contribute to DM2 pathogenetic
mechanisms.
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Introduction
Myotonic Dystrophy (DM) is an autosomal dominant disease
and the most common muscular dystrophy of the adult, with
a prevalence of 1/8,000 worldwide [1]. DM is a progressive
multisystemic disorder characterized by a variety of manifestations
that include muscle hyperexcitability (myotonia), muscular dys-
trophy, cardiac conduction defects, dilated cardiomyopathy,
insulin-resistance, cataracts, neurological involvement, and a mul-
tiplicity of serological abnormalities. The severity and the number
of symptoms are highly variable and can range from minimal
signs, to facial and muscle wasting and weakness, to severe
congenital disorder [1]. Respiratory failure and cardiac arrhyth-
mias are among the main causes of premature death in DM
patients [1]. At the histological level, pathological features of the
DM skeletal muscle include the concomitant presence of atrophic
and hypertrophic myofibers, increased number of central nuclei,
and presence of fibers with nuclear clumps [2].
Two types of DM have been described. The most common
form of DM, named type 1 or Steinert’s disease (DM1, OMIM
160900), is caused by an expanded (CTG)n in the 39 untranslated
region of the Dystrophia Myotonica Protein Kinase gene [3,4,5]. The
second form of DM is named type 2 or PROximal Myotonic
Myopathy-PROMM (DM2, OMIM 602688): it displays a preva-
lently proximal impairment and milder clinical symptoms than
DM1, since it does not show a congenital form or anticipation i.e.
a phenomenon of progressively earlier and more severe manifes-
tation of the disease. DM2 is caused by the expansion of
a tetranucleotidic repetition (CCTG)n in the first intron of the
CCHC-type zinc finger, nucleic acid binding protein (CNBP) [6].
Several lines of evidence indicate that an RNA-mediated toxic
gain-of-function is the common pathogenetic mechanism of the
two DM types. In both DM1 and DM2, the mutation causes the
accumulation of the expanded CUG/CCUG transcripts into
discrete nuclear RNA foci. The expanded RNA that is trapped in
the nucleus, deregulates the interaction of RNA binding proteins,
which are essential for mRNA splicing and other cell processes,
leading to aberrant RNA maturation and cell dysfunction [7].
MicroRNAs (miRNAs) are short non-coding RNAs that
regulate the stability and/or the translational efficiency of target
mRNAs. miRNAs have a very pervasive role: bioinformatic studies
estimate that .60% of all transcripts are regulated by one or more
miRNA [8]. Indeed, miRNAs have a demonstrated impact on
virtually all cell functions, including differentiation, proliferation
and apoptosis [9,10]. Specifically, miRNA sequences can regulate
skeletal and cardiac muscle function in both development and
disease, such as ischemia and muscular dystrophy [11,12].
We and others demonstrated miRNA deregulation in Du-
chenne Muscular Dystrophy patients and in mdx mice, both
lacking a functional dystrophin gene [13,14,15,16]. Moreover,
Eisenberg and collaborators described miRNA expression profiles
in skeletal muscle from various human primary muscle disorders
and identified a series of miRNAs that are deregulated in almost
all myopathies analyzed [14]. Finally, we and others analyzed the
expression of miRNAs in DM1 and identified specific miRNAs
displaying altered expression and localization [17,18,19].
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In this study, miRNA expression profiles were measured in the
skeletal muscle of DM2 patients. We identified a subset of
miRNAs that are specifically deregulated potentially contributing
to DM2 pathogenetic mechanisms.
Materials and Methods
Patient Selection and Skeletal Muscle Biopsies
This study was authorized by the Institutional Ethics Commit-
tee (ASL MI2) and was conducted according to the principles
expressed in the Declaration of Helsinki, the institutional
regulation and Italian laws and guidelines. All biopsy specimens
were taken after specific written informed consent was obtained.
Human muscle biopsies from biceps brachii were harvested under
sterile conditions and snap-frozen in liquid nitrogen. Clinical
diagnosis of DM2 patients was based upon the criteria set by the
International Consortium for Myotonic Dystrophies [20]. Fluo-
rescence in situ hybridization was performed on frozen muscle
sections to confirm DM2 diagnosis according to Cardani et al.
[21]. Control (CTR) biopsies were from subjects admitted with
suspected neuromuscular disorder of undetermined nature. CTR
biopsies did not show overt signs of muscle pathology on
histological and immunohistochemical examination. All muscle
biopsies were processed by the same pathology team. Immuno-
histochemical analysis of atrophy and hypertrophy in fast and slow
fibers was carried out as previously described [22].
RNA Isolation and miRNA Profiling
Total RNA was extracted by Trizol (Invitrogen) and the
TissueLyser system (Qiagen). TaqMan Low Density miRNA
arrays v.2 (Applied Biosystems) were used to measure 365 human
mature miRNAs, as previously described [23]. After median Ct
value normalization, relative miRNA expression was calculated
with the 22DDCt method [24]. We further analyzed those miRNAs
with a Ct#33, displaying a significant fold change $2. Data
distribution was evaluated by the Kolmogorov-Smirnov’s normal-
ity test. Permutational multivariate analysis of variance was
performed by the multivariate non-parametric PERMANOVA
test, using 9,999 permutations, Bonferroni post-hoc test and
Gower test for distance measurement. Adjusted p,0.05 was
considered as statistically significant.
mRNA Profiling
Gene expression profiles were measured using the Gene Chip
Human Exon 1.0 ST Array (Affymetrix). One hundred ng of total
RNA were analyzed according to the manufacturer instructions.
Data analysis was computed using Partek Genomics Suite (Partek
Inc.) according to MIAME guidelines. The output signals were
normalized using the Partek Robust Multi-Chip Average analysis
adjusted for the GC content of probe sequence (GCRMA). The
genes that were differentially expressed among the two classes
were identified using the Analysis of Variance (ANOVA) as
implemented in the Partek Gene Expression tool. An estimate of
the associated False Discovery Rate (FDR) was computed per gene
using the method of Benjamini and Hochberg [25]. mRNA
transcripts were considered to be significantly differentially
expressed if they obtained ANOVA p-value,0.005 and
FDR,0.15.
qPCR Assay
Individual mature miRNAs were measured using TaqMan
MicroRNA single assays (Applied Biosystems) and samples were
normalized to miR-16 expression [26]. MiRNA profiling indicated
that miR-16 was not-modulated in DM2 patients. mRNA levels
were measured using the SYBR-GREEN qPCR method (Applied
Biosystems) and samples were normalized to GAPDH. For both
miRNAs and mRNAs, relative expression was calculated using the
comparative Ct method 2–DDCt [24]. Each sample was measured
in triplicate and values were averaged.
Table 1. Characteristics of Profiling Cohorts (Mean6Se).
PARAMETER DM2 (N=13) CONTROLS (N=13) p
AGE (years) 56.961.9 49.362.5 ns
SEX (f/m) 5/8 5/8 ns
STRENGHT (biopsied muscle) (MRC scale) 4.560.1 4.960.04 ns
STRENGHT (Megascore on 15 muscles, MRC scale) 137.469.1 145.666.8 ns
MYOTONIA (%) 85 0 ,0.0001
GLUCOSE (mg/dl) (n.v.70–110) 101.4616.0 86.068.5 ns
DIABETES MELLITUS (%) 18 0 ns
CPK (IU/l) (n.v. m,190, f,167) 292.763.5 236.4667.1 ns
FT3 (pg/ml) (n.v. 1.5–4.1) 3.063.1 1.760.5 ns
FT4 (ng/dl) (n.v. 0.8–1.9) 1.360.3 1.260.3 ns
TSH (mIU/ml) (n.v. 0.4–4.0) 1.060.2 0.760.2 ns
ECG-QRS duration (msec) (n.v. 60–100) 94.3616.4 85.9612.1 ns
EF (%) (n.v..50) 54.569.7 64.0619.3 ns
ICM (%) 9 0 ns
SERIC b-GLOBULIN (%) 12.361.7 14.162.0 ns
CATARACT (%) 70 0 ,0.0005
Abbreviations: MRC scale=Medical Research Council scale (0–5 grade); CPK=Creatine PhosphoKinase; FT3= free-triiodothyronine; FT4= free-thyroxine;
TSH= thyroid stimulating hormone; ECG= electrocardiogram; QRS duration=QRS complex of ECG corresponds to the depolarization of the right and left ventricles
of the human heart; EF= ejection fraction; ICM= ischemic cardiomyopathy.
doi:10.1371/journal.pone.0039732.t001
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DM2 miRNA Score
To calculate the DM2 miRNA scores, the median fold change
of all the deregulated miRNAs was calculated for each subject. For
negatively regulated miRNAs, the minus sign was inverted before
calculating the median.
Bioinformatic Analysis
Bioinformatic prediction of miRNA target genes was performed
using miRonTop [27]. Predicted miRNA target genes were
compared to differently expressed genes (p#0.01) displaying an
opposite modulation with their corresponding miRNA. The
correlation analysis between mRNA and miRNA expression was
evaluated by the quantitative trait tool in BRB ArrayTools
(Richard Simon and BRB-ArrayTools Development Team)
(p#0.01).
Pathway analysis was performed using Ingenuity Pathways
Knowledge Base (version 8.8, Ingenuity Systems) as reference set
and assuming direct and indirect relationships. A Fisher’s exact
test p-value ,0.05 was deemed as statistically significant.
Statistics
Continuous variables are expressed as mean6standard error
(SE), unless indicated differently. For group-wise comparisons,
Mann–Whitney test or t-test were used as appropriate. For the
DM2 miRNAs-score, Mann-Whitney’s variance analysis was used.
The ability to discriminate between the DM2 and control groups
was characterized by the receiver operating characteristic (ROC)
curve, and the area under the ROC curve (AUC) was calculated.
Spearman rank correlation was used to compare the DM2
miRNA score with atrophy/hypertrophy fiber index. All tests were
performed 2-sided and a p#0.05 was considered as statistically
significant. For statistical analysis and heat map data visualization,
GraphPad Prism v.4.03 (GraphPad Software Inc.) and Genesis
1.7.2 (Graz University of Technology, Institute for Genomics and
Bioinformatics) softwares were used, respectively.
Results
Identification of Differentially Expressed miRNAs in DM2
Patients
Patients were selected so that DM2 and controls (CTR),
displayed similar age and sex distribution (Table 1). Most DM2
patients had myotonia and cataract, two disease hallmarks, while
differences in other clinical parameters were not significant. The
experimental plan is schematized in Figure 1.
Skeletal muscle biopsies were harvested from 10 DM2 patients
and 9 CTR, and total RNA was extracted. MiRNA profiling
showed that, out of 365 miRNA measured, 203 and 199 were
readily detectable (Ct,33) in DM2 and CTR groups, respectively
(see Gene Expression Omnibus database, GEO, GSE37794 for
a complete gene list). Statistical analysis showed that 20 miRNAs
were significantly modulated $2-fold in DM2 compared to CTR
(Fig. 2) and these miRNAs were validated by more sensitive and
specific qPCR assays. This validation step included the same
patients and CTR used for profiling, and was extended to three
more DM2 and four more CTR (n= 13 for each group).
Moreover, we added six more miRNAs to the 20 modulated
miRNAs: the muscle-specific miRNAs, miR-1 and miR-206
[28,29], miR-221-3p, which is co-transcribed with miR-222-3p,
miR-193a-3p and miR-146a since they belong to miR-193 and
miR-146 families, respectively, and miR-499-5p, which is down-
stream of miR-208a network [30]. We found that 11 miRNAs
were validated as significantly deregulated in DM2 patients (Fig. 3).
These DM2 miRNAs were also tested in an age and sex
matched cohort of DM1 patients. We found that miR-193b-3p,
miR-208a and miR-381 showed a similar significant modulation
also in these patients (Fig. 3).
A DM2 miRNA Score Discriminates between Patients and
Controls and Correlates with Myofiber Atrophy and
Hypertrophy
DM2 deregulated miRNAs were also considered collectively:
median fold change of the differentially expressed miRNAs was
used to calculate a ‘‘DM2 miRNAs score’’ in each patient or CTR
subject. The DM2 miRNA score allowed a significant separation
between the DM2 and the CTR groups, with a median score of
2.3 in the DM2 group and 0.6 in the CTR group (Figure 4A). The
ability of the DM2 miRNA score to discriminate DM2 patients
from CTR was also demonstrated by the Receiver-Operator
Characteristic (ROC) curve (Figure 4B). A ROC curve allows to
visualize the reciprocal relationship between sensitivity and
specificity when discriminating between control and DM2 values.
The calculation of sensitivity and specificity depends on the
threshold value used to separate the two classes; if the threshold
value used is high, the specificity of the test increases, but the
sensitivity decreases, conversely if the threshold is low, the test’s
sensitivity is increased [31,32]. By using a threshold score of 1.15
we achieved a sensitivity of 100% and a specificity of 92.3% for the
identification of DM2 patients. Moreover, the Area Under Curve
(AUC), which quantifies the overall ability of the test to
discriminate between normal and diseased individuals, was 0.96,
where perfect test (with zero false positives and zero false negatives)
has an area of 1.00 [33].
Figure 1. Experimental Plan. miRNA (blue) and mRNA (red)
expression patterns were determined in DM2 and CTR, and significantly
modulated miRNAs and mRNAs were identified. Validation was
performed by qPCR for both miRNAs and mRNAs in 13 DM2 patients
and 13 CTR. miRNA targets among the mRNAs identified by Class
Comparison analysis were predicted by dedicated softwares. Only
miRNA/mRNA couples displaying inverse significant correlation were
selected and then analyzed by Ingenuity Pathway Analysis software
that allowed to identify enriched molecular pathways and functions.
doi:10.1371/journal.pone.0039732.g001
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At the histological level, a DM2 hallmark is represented by the
concomitant presence of atrophic and hypertrophic myofibers,
preferentially in type 2 (fast) fibers [2,34,35] (Figure 5A). We found
that DM2 miRNA score correlated with both the atrophy (AR)
and the hypertrophy (HR) index, but only in type 2 myofibers
(Figure 5B).
Transcriptome Analysis and Predicted miRNA/mRNA
Interactions
To investigate the implications of miRNA dysregulations
identified in DM2 patients, we tested their impact on the
transcriptome using high-density oligonucleotide microarrays.
The same RNAs used for miRNA profiling were analyzed, with
the addition of one extra control (total, 10 DM2 and 10 CTR) (see
Gene Expression Omnibus database, GEO, GSE37084 for
a complete gene list). As expected, unsupervised hierarchical
clustering analysis segregated the profiles of DM2 and CTR (Fig.
S1). Class Comparison analysis versus the CTR group was
performed identifying 724 non redundant transcripts differentially
expressed in DM2 patients. qPCR validation allowed to confirm
10 out of 12 tested genes (not shown).
Next, we attempted to identify the contribution of miRNA
deregulation to differential gene expression. Given the inhibitory
nature of miRNAs [8,36], mRNA displaying reciprocal modula-
tion to DM2 miRNAs were selected. These transcripts were
further filtered using target identification algorithms, to predict
direct binding events. The application of these three sequential
filers allowed the identification of 1,093 miRNA/mRNA interac-
tions (Table S1).
It is worth noting that several mRNAs were predicted targets of
more than one miRNA deregulated in DM2, with a potential
signal reinforcement. A randomly selected subset of the identified
miRNA-target modulations was further tested by qPCR and 15
out of 22 were validated (Fig. 6). The remaining 7 interactions
originated from 3 transcripts (CARM1, NXN and YIPF7) that
were not detectable in most controls and DM2 samples.
Pathways Analysis of Gene Expression Changes
To facilitate the interpretation of the complex gene expression
changes observed, we used Ingenuity Pathway Analysis software
(IPA) exploring enriched biological functions and pathways. Both
global gene expression changes and DM2 miRNA/mRNA
interactions were analyzed.
To assess the potential functional relevance of the overall gene
expression changes observed in DM2 patients, differentially
expressed genes, analyzed by Class Comparison, were uploaded
to the IPA database. Several interesting pathways and functions
were enriched significantly in the DM2 group compared to CTR,
such as ‘‘Mitochondrial Dysfunctions’’, ‘‘TGF-b Signaling’’, ‘‘In-
sulin Receptor Signaling’’, ‘‘Calcium Signaling’’ for the pathways
and ‘‘Skeletal and Muscular System Development’’, ‘‘Cell Cycle’’,
Figure 2. Profiling of miRNAs in DM2 patients and CTR. In the
heat map on the left, mean miRNAs expression values are shown in
a log2 scale (-DDCt), where red and green indicate positive and negative
modulation respectively. The table on the right shows the same values
in a linear scale (DM2= 13, CTR = 13; *p#0.05 **p#0.01).
doi:10.1371/journal.pone.0039732.g002
Figure 3. Validation of miRNA modulations in DM1 and DM2
patients. In the heat map on the left, the mean values of miRNA
expression in both DM1 and DM2 compared to controls are shown in
a log2 scale (-DDCt), where red and green indicate positive and negative
modulation respectively. On the right, the table shows the same values
in a linear scale; statistically significant differences are highlighted in
bold (DM2 n = 13, DM1 = 16, CTR n = 13; *p#0.05 **p#0.01
***p#0.001).
doi:10.1371/journal.pone.0039732.g003
microRNAs Expression in DM2
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‘‘Cell Death’’, ‘‘Skeletal and Muscular Disorders’’ for the enriched
functions (Table S2 and S3). Moreover, ‘‘Cardiac Dilation’’,
‘‘Cardiac Hypoplasia’’ and ‘‘Cardiac Artheriopathy’’ among the
toxic functions were also found enriched (Table S4). Complete lists
of enriched categories can be found in Table S8.
IPA analysis of miRNAs predicted targets differentially modu-
lated in DM2 patients identified several important pathways
enriched, such as: ‘‘Insulin Receptor Signaling’’, ‘‘Integrin
Signaling’’, ‘‘PI3K/AKT Signaling’’ and ‘‘TGF-b Signaling’’
(Table 2 and Table S5). ‘‘Skeletal and Muscular Disorders’’,
‘‘Ophthalmic Diseases’’ and ‘‘Endocrine System Disorders’’ and
‘‘Cardiac Damage’’, ‘‘Cardiac Dilation’’ and ‘‘Heart Failure’’ were
relevant enriched functions (Table 2 and Table S6) and toxic
functions (Table 2 and Table S7), respectively, and all the enriched
Figure 4. Discrimination between DM2 and control groups using the DM2 miRNA score. (A) Dot plot of the DM2 miRNA score in DM2
patients and CTR. The segments among the dots indicate median values for each group and the difference is statistically significant (DM2=13, CTR
n= 13; p,0.0001). (B) ROC curve displaying DM2 miRNA score discrimination between the DM2 and CTR groups (AUC= 0.96).
doi:10.1371/journal.pone.0039732.g004
Figure 5. Correlation of atrophy and hypertrophy with DM2miRNAs score. A) Representative stainings of transverse sections of frozen DM2
muscle biopsies. Top panel shows a hematoxylin and eosin staining; bottom panel shows an immunostaining for fast myosin heavy chain. Atrophic
(blue arrows) and hypertrophic (asterisks) myofibers, as well as nuclear clumps (red arrows) and internal nuclei (black arrows) are highlighted. B)
Spearman’s correlation between DM2 miRNAs score and Atrophy (AR) or Hypertrophy (HR) indexes in fast and slow fibers (DM2 n= 13; CTR n= 9).
doi:10.1371/journal.pone.0039732.g005
microRNAs Expression in DM2
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categories are showed in Table S9, where the selected categories of
Table 2 are highlighted in bold.
Discussion
Understanding the molecular mechanisms triggered by the
tetranucleotide expansion in the Zinc Finger Protein-9 gene is of
great importance to gain insight into the molecular mechanisms
underpinning DM2 disease. For the first time, we measured the
miRNA profile of skeletal muscle biopsies of DM2 patients,
identifying 11 deregulated miRNAs. We and others found that
miR-221-3p, miR-381, miR-34a-5p, miR-34c-5p, miR-146b-5p,
and miR-193b-3p were similarly modulated in muscular diseases
other than DM2 [13,14] (Table S10), suggesting potential
similarities in certain aspects of the pathogenetic mechanisms.
The DM2 miRNAs were also measured in DM1 patients and
Figure 6. Validation of miRNA/mRNA interactions in DM2 patients. Validation by qPCR of the expression of randomly selected mRNAs either
up-(A) and down-(B) regulated in DM2 patients vs CTR. Expression level compared to CTR of the targeting miRNA is indicated for each mRNA
(DM2=12, CTR= 10;*p#0.05; **p#0.01; ***p#0.001; ****p#0.0001).
doi:10.1371/journal.pone.0039732.g006
Table 2. Pathways and Functions Analysis by IPA.
PATHWAYS p-value ratio enrichment index
Insulin Receptor Signaling 0.002 11/139 263
Integrin Signaling 0.003 14/209 223
FAK Signaling 0.02 7/102 345
PI3K/AKT Signaling 0.03 8/140 285
RAR Activation 0.03 10/183 275
TGF-b Signaling 0.04 6/89 478
FUNCTIONS p-value ratio enrichment index
Skeletal and Muscular System Development and Function 7.8E206 50/2849 15
Skeletal and Muscular Disorders 2.7E204 142/3851 11
Neurological Disease 2.4E204 179/4743 9
Cardiovascular Disease 9.4E204 110/2663 159
Metabolic Disease 9.4E204 124/2496 17
Endocrine System Disorders 1.4E203 10/2271 19
Cell Growth and Proliferation 2.1E203 36/2884 15
Cardiovascular System Development and Function 2.7E203 11/2738 15
Ophthalmic Disease 2.7E203 3/987 43
TOXIC FUNCTIONS p-value ratio enrichment index
Cardiac Damage 3.0E202 1/88 481
Cardiac Dilation 3.0E202 4/83 510
Heart Failure 4.8E202 11/330 128
Table legend:
ratio=number of modulated genes/total number of genes present in the relevant IPA category.
enrichment index= ratio between observed genes and number of genes expected by chance in each category.
doi:10.1371/journal.pone.0039732.t002
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miR-193b-3p, miR-208a and miR-381 were similarly modulated.
The differences displayed by the remaining miRNAs did not
reach statistical significance, possibly due to insufficient patient
numerosity.
We found that a DM2 miRNA score allowed to discriminate
DM2 patients from CTR with a good sensitivity and specificity.
Furthermore, DM2 miRNA score correlated to atrophy and
hypertrophy of type 2, fibers that are particularly affected in DM2,
indicating that the deregulated miRNAs were related to the
disease pathogenetic mechanism. Further studies are granted to
explore DM2 miRNA score diagnostic potential.
The up-regulation of all members of miR-34 family appears
particularly significant, given miR-34 role in cell differentiation,
apoptosis and senescence [37]. It is also worth noting the up-
regulation of miR-221-3p, playing an important role in myotube
maturation and in the maintenance of the myofibrillar organiza-
tion [38]. Finally, we demonstrated the down-regulation of miR-
125b-5p, which negatively regulates myoblast differentiation and
muscle regeneration [39].
In an attempt to gain further insight into the underlying
molecular mechanisms, we investigated the transcripts predicted to
be regulated by the DM2 miRNAs. In most circumstances,
miRNA binding induces the degradation of the target mRNA
[8,40]. Thus, we measured the transcriptome of DM2 patients and
used target prediction softwares [27] to identify the genes
potentially regulated by the DM2 miRNAs, directly. To minimize
the number of false positive miRNA/mRNA interactions, we used
three selection criteria: 1) only significantly modulated miRNAs
and mRNAs were considered; 2) given the inhibitory nature of
miRNA function [8,36], only miRNA/mRNAs couples displaying
a statistically significant reciprocal correlation of their expression
levels were included; 3) among the genes passing filters 1 and 2,
predicted targets were identified by MiRonTop [27]. After this
highly selective selection, 1,093 miRNA/mRNA interactions were
identified. Several mRNAs were targeted by more than one
miRNA, leading to a potential reinforcement of the final
deregulation. For instance, EGF was a predicted target not only
of the three members of the miR-34 family, but also of miR-208a
and miR-381.
The increase of MBNL2, a miR-378a-3p predicted target, was
another interesting finding. Indeed, a hallmark of DM2 is the
nuclear accumulation of (CCUG)n repeats that bind and sequester
muscleblind-like proteins MBNL1, MBNL2 and MBNL3
[41,42,43]. The observed induction of MBNL2 mRNA expression
in DM2 may be an adaptive response counteracting the decreased
bioavailability of MBNL.
To the best of our knowledge, this represents the first study
investigating miRNA/transcriptome interactions in DM2 patients,
paving the way to further investigations that are necessary to
formally demonstrate cause/effect relationships between the DM2
miRNAs and their targets. Moreover, a potential caveat of our
analysis is represented by the heterogeneity of the cell populations
composing skeletal muscle tissue. Albeit myofibers constitute the
majority of the tissue mass, it is possible that certain miRNAs and
target mRNAs are deregulated in different cell types.
A bioinformatic analysis of the pathways and functions revealed
that DM2 miRNA targets were potentially involved in most DM2
pathogenetic mechanisms. The functions ‘‘Skeletal and Muscular
System Development and Function’’, ‘‘Neurological Disease’’ and
‘‘Skeletal and Muscular Disorders’’ are of obvious relevance. The
‘‘PI3K/AKT signaling ‘‘and the ‘‘TGF-b signaling’’ pathways
seem particularly important. Indeed, dysregulation of TGF-
b signaling has been implicated in various pathological conditions
affecting skeletal muscle, both inherited and acquired [44], and
Akt2 expression is greatly increased during skeletal muscle cell
differentiation and myocyte growth, suggesting a critical role of
Akt2 in myogenesis [45,46,47]. Thus, both PI3K/AKT and TGF-
b signaling may relate to the atrophic/hypertrophic myofiber
alterations characterizing DM2.
DM2 is a multisystemic disease. Indeed, other pathways and
functions are linked to aspects of DM2 that do not affect the
skeletal muscle directly. The ‘‘Insulin Receptor Signaling’’
pathway as well as the ‘‘Metabolic Disease’’ and ‘‘Endocrine
System Disorders’’ functions suggest the involvement of the
relevant miRNA/mRNA couples in insulin resistance, a classic
DM clinical feature, predisposing to Type 2 diabetes [1,34,48].
Albeit the assayed tissue was skeletal muscle, many functions
and toxic functions related to heart and cardiovascular disease, in
keeping with the cardiac conduction defects and the dilated
cardiomyopathy commonly observed in DM. Another DM
hallmark is cataract; thus, it was interesting that the ‘‘Ophthalmic
Disease’’ function was also represented.
Looking at the global alterations of the transcriptome, to the
best of our knowledge, only one previous study exists [22].
However, a direct comparison with our investigation is limited by
the fact that Vihola et al. narrowed their scope to 327 probesets
functionally associated with muscle a priori. Nevertheless, it is
interesting to note that both studies identified several altered genes
involved in Calcium handling and signaling, that may relate to the
abnormal calcium handling and myotonia observed in DM
[49,50,51]. Moreover, in keeping with increased oxidative stress
levels measured in DM1 patients [52], we found that ‘‘NRF2-
mediated Ox-Stress Response’’ and ‘‘mitochondrial dysfunction’’
pathways were also enriched.
Conclusions
In conclusion, we identified a small subset of miRNA whose
expression was deregulated in DM2. These findings may improve
our understanding of the molecular mechanisms linking (CCTG)n
expansion to disease.
Supporting Information
Figure S1 Unsupervised hierarchical clustering of
mRNA expression differentiating DM2 (n=10) from
controls (n= 10). Each row represents an mRNA, and each
column represents an individual. A color code represents the
relative intensity of the expression signal, with red indicating high
expression and blue indicating low expression.
(PPT)
Table S1 Transcriptome analysis identified 1,093
miRNA/mRNA interactions. Table represents the identified
miRNAs/mRNA interactions, where green and red colours
indicate down- or up-regulation of miRNA or mRNA compared
to controls, respectively.
(XLS)
Table S2 Ingenuity Pathway Analysis (IPA) of important
pathways, functions and toxic functions enriched in
transcriptome. Some important enriched pathways, functions
and toxic functions and relative miRNA/mRNA interactions are
shown; green and red colours indicate down- or up-regulation of
miRNA or mRNA, respectively. Complete lists of enriched
categories can be found in Table S8.
(XLS)
Table S3 Ingenuity Pathway Analysis (IPA) of important
pathways, functions and toxic functions enriched in
transcriptome. Some important enriched pathways, functions
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and toxic functions and relative miRNA/mRNA interactions are
shown; green and red colours indicate down- or up-regulation of
miRNA or mRNA, respectively. Complete lists of enriched
categories can be found in Table S8.
(XLS)
Table S4 Ingenuity Pathway Analysis (IPA) of important
pathways, functions and toxic functions enriched in
transcriptome. Some important enriched pathways, functions
and toxic functions and relative miRNA/mRNA interactions are
shown; green and red colours indicate down- or up-regulation of
miRNA or mRNA, respectively. Complete lists of enriched
categories can be found in Table S8.
(XLS)
Table S5 Ingenuity Pathway Analysis (IPA) of important
pathways, functions and toxic functions enriched in
miRNAs targets analysis. Some important enriched pathways,
functions and toxic functions in miRNA/mRNA interactions are
shown; green and red colours indicate down- or up-regulation of
miRNA or mRNA, respectively. Complete lists of enriched
categories can be found in Table S9.
(XLS)
Table S6 Ingenuity Pathway Analysis (IPA) of important
pathways, functions and toxic functions enriched in
miRNAs targets analysis. Some important enriched pathways,
functions and toxic functions in miRNA/mRNA interactions are
shown; green and red colours indicate down- or up-regulation of
miRNA or mRNA, respectively. Complete lists of enriched
categories can be found in Table S9.
(XLS)
Table S7 Ingenuity Pathway Analysis (IPA) of important
pathways, functions and toxic functions enriched in
miRNAs targets analysis. Some important enriched pathways,
functions and toxic functions in miRNA/mRNA interactions are
shown; green and red colours indicate down- or up-regulation of
miRNA or mRNA, respectively. Complete lists of enriched
categories can be found in Table S9.
(XLS)
Tables S8 Ingenuity Pathway Analysis (IPA) of enriched
categories in transcriptome. Statistical significance and
complete list of involved molecules in each enriched categories
are shown.
(XLS)
Tables S9 Ingenuity Pathway Analysis (IPA) of enriched
categories in miRNAs targets analysis. Statistical signifi-
cance and complete list of involved molecules in each enriched
categories are shown.
(XLS)
Table S10 Comparison of miRNAs dysregulations with
previous studies. The modulation of dysregulated miRNAs in
DM2 patients were compared to previously published data on
miRNAs dysregulation in muscular diseases. Green and red
colours indicate down- or up-regulation of miRNAs, respectively.
(XLS)
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